JPMorgan raised the firm’s price target on Olema Oncology (OLMA) to $58 from $55 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology space.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OLMA:
- Olema Oncology price target lowered to $27 from $38 at Goldman Sachs
- Olema Oncology price target lowered to $38 from $40 at Guggenheim
- Olema Oncology price target raised to $62 from $60 at Citi
- Olema Pharmaceuticals: Palazestrant Phase III Upside and Differentiated Pipeline Underpin Buy Rating
- Buy Rating Reaffirmed on Palazestrant’s Differentiated Phase 3 Program and Favorable Risk‑Reward Profile for Olema